License Option Agreement with Pfizer for Voyager Therapeutic's Next-Generation TRACERᵀᴹ AAV Capsids Voyager Therapeutics, a gene therapy company developing adeno-associated virus (AAV) platform technologies, announced an agreement through which Pfizer may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of…..
Trend Chart on Innovative Bioindustries April 12th FEATURE STORY ● Sirnaomics releases positive interim data from phase II Trial of siRNA candidate studies Sirnaomics, a US-China RNAi therapeutics company, reported on April 9th positive interim results from a Phase II trial of its RNA treatment for non-melanoma skin cancer. STP705…..